Trials / Recruiting
RecruitingNCT06783829
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4394 Injection in Subjects With Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4394 | SHR4394 |
Timeline
- Start date
- 2025-01-22
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2025-01-20
- Last updated
- 2025-02-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06783829. Inclusion in this directory is not an endorsement.